Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines

by NASDAQ Market News May 13, 2019

NASDAQ Market News
Click here to email author

CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.

Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

Ads